Heart Rhythm Society (HRS)

The Heart Rhythm Society (HRS) is the primary U.S. medical society for electrophysiology (EP). The organization promotes education and advocacy for cardiac arrhythmia professionals and patients, including setting policy guidelines and offering expert consensus.

RSS icon
HRS President, Mina Chung, MD, FHRS, staff cardiologist and Professor of Medicine in the Section of Pacing and Electrophysiology, Heart & Vascular Institute, Cleveland Clinic. Explains HRS accomplishments in the past year in terms of advocacy efforts and policy concerns impacting EP. #HRS2026 #EPeeps

Heart Rhythm 2026: Electrophysiologist Mina Chung discusses CPR, PFA and much more

Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.

Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 

GLP-1 receptor agonists (GLP-1-RAs) have become the wonder drug not only of weight loss, but also for improving cardiovascular health in a growing number of positive cardiovascular trials. The latest study of more than 13,000 patients presented at Heart Rhythm 2026 this week showed the GLP-1 reduce atrial fibrillation (AFib) and survival, even after accounting for the drug’s impact on weight loss.

Multiple GLP-1 drugs linked to lower AFib risk

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 

The U.S. Food and Drug Administration (FDA) has granted market clearance for Biotronik's Acticor Sky and Rivacor Sky implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The new technology will be launches at the Heart Rhythm Society (HRS) annual meeting this week. #HRS2026

FDA approves 2 implantable heart devices from Biotronik

These devices were built to provide better patient data and improve clinician workflows. They will be on display at Heart Rhythm 2026 in Chicago. 

Heart Rhythm 2025 Heart Rhythm Society President Kenneth A. Ellenbogen, MD

Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

heart drugs with stethoscope

Long-term antidepressant use may increase risk of sudden cardiac death

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

Congress Senate Washington D.C. DC

EP advocacy group details 6 key policy issues

The Heart Rhythm Society's advocacy arm is monitoring such issues as prior authorization, outpatient payment policies and cancelled research funding. 

Biotronik has secured U.S. Food and Drug Administration (FDA) approval for its Solia CSP S pacing lead for left bundle branch area pacing (LBBAP).

FDA approves new Biotronik pacing lead for LBBAP

The next-generation device includes a stylet-driven lead and a fixed helix. It was designed and developed specifically with LBBAP in mind. 

Displaying 1 - 8 of 97
Design by Adaptive Theme